secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001140361-23-008940
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma reports Q4 2022 net loss of $66.7M; cash $399.7M; pipeline on track for 2023 regulatory filings
--------------------------------------------------------------------------------

- Net loss $66.7M ($0.92/sh) in Q4 2022 vs $44.2M ($0.69) in Q4 2021; full-year net loss $221.9M ($3.26) vs $169.1M ($2.67).
- Cash, cash equivalents and investments $399.7M as of Dec 31, 2022; expected runway through 2024.
- Plans BLA submissions: LAD-I in Q2 2023, Fanconi Anemia in Q4 2023; Phase 2 pivotal for Danon Disease (RP-A501) starts Q2 2023.
- FDA granted RMAT designation for RP-A501 (Danon Disease); acquired Renovacor in Dec 2022 adding BAG3-DCM program.
- Raised $197.7M in 2022 via follow-on, ATM, and Renovacor cash; appointed new board member and executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036123008940/0001140361-23-008940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036123008940/brhc10048939_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-008940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer